Casdin Capital’s Sage Therapeutics SAGE Stock Holding History

Casdin Capital’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-65,000	Closed	-$1.96M	–	30
2016 Q2	$1.96M	Buy	+65,000	New	+$2.17M	1.95%	19

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Casdin Capital's SAGE Position: Q3 2023 in Review

Casdin Capital sold out of Sage Therapeutics (SAGE) in Q3 2023, closing a stake of 90,000 shares — an estimated $4.23M sold.

Casdin Capital first reported a position in SAGE in Q4 2015 and held it in 19 quarters. The position peaked at $73.2M in Q2 2019. 194 funds tracked by Wall St. Rank hold SAGE as of Q3 2023.

Casdin Capital reported no remaining Sage Therapeutics position as of Q3 2023 after selling out during the quarter.
Casdin Capital sold 90,000 Sage Therapeutics shares in Q3 2023, an estimated $4.23M.
Casdin Capital first reported a position in Sage Therapeutics in Q4 2015 and held it in 19 quarters.
Casdin Capital's Sage Therapeutics position peaked at $73.2M in Q2 2019.
194 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2023.

Based on Casdin Capital's 13F filing for Q3 2023, filed 14 Nov 2023.